Johnson & Johnson To Go Ex-Dividend On November 26th, 2024 With 1.24 USD Dividend Per Share
November 24th (Eastern Time) - $Johnson & Johnson(JNJ.US)$ is trading ex-dividend on November 26th, 2024.Shareholders of record on November 26th, 2024 will receive 1.24 USD dividend per share on
Johnson & Johnson (JNJ.US) has submitted a regulatory application to the FDA for its antibody therapy to treat moderate to severe active ulcerative colitis.
Johnson & Johnson (JNJ.US) announced that it has submitted a supplemental Biological Product License Application (sBLA) to the FDA in the USA.
Hedge Funds Bet Big On Johnson & Johnson (JNJ): Top Healthcare Stock to Watch
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
Sanofi Becomes Latest Drugmaker to Challenge HHS Over 340B Drug-discount Program
Express News | Johnson & Johnson is seeking approval from the FDA to use the subcutaneous induction therapy of TREMFYA (GUSELKUMAB) to treat ulcerative colitis.